Germany
· Delayed Price · Currency is EUR Atai Life Sciences Statistics
Total Valuation
ETR:9VC has a market cap or net worth of EUR 254.78 million. The enterprise value is 223.84 million.
| Market Cap | 254.78M |
| Enterprise Value | 223.84M |
Important Dates
The next estimated earnings date is Wednesday, May 14, 2025.
| Earnings Date | May 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.84% |
| Shares Change (QoQ) | +0.06% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 109.00M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 856.43 |
| PB Ratio | 2.26 |
| P/TBV Ratio | 2.34 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.55 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -2.81 |
Financial Position
The company has a current ratio of 3.21, with a Debt / Equity ratio of 0.23.
| Current Ratio | 3.21 |
| Quick Ratio | 2.55 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.33 |
| Interest Coverage | -31.94 |
Financial Efficiency
Return on equity (ROE) is -83.16% and return on invested capital (ROIC) is -30.48%.
| Return on Equity (ROE) | -83.16% |
| Return on Assets (ROA) | -27.54% |
| Return on Invested Capital (ROIC) | -30.48% |
| Return on Capital Employed (ROCE) | -74.22% |
| Revenue Per Employee | 5,509 |
| Profits Per Employee | -2.67M |
| Employee Count | 54 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -31.71% in the last 52 weeks. The beta is 1.25, so ETR:9VC's price volatility has been higher than the market average.
| Beta (5Y) | 1.25 |
| 52-Week Price Change | -31.71% |
| 50-Day Moving Average | 1.42 |
| 200-Day Moving Average | 1.34 |
| Relative Strength Index (RSI) | 50.51 |
| Average Volume (20 Days) | 213 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.33 |
Income Statement
In the last 12 months, ETR:9VC had revenue of EUR 297,497 and -144.18 million in losses. Loss per share was -0.90.
| Revenue | 297,497 |
| Gross Profit | 297,497 |
| Operating Income | -96.37M |
| Pretax Income | -145.78M |
| Net Income | -144.18M |
| EBITDA | -95.91M |
| EBIT | -96.37M |
| Loss Per Share | -0.90 |
Balance Sheet
The company has 60.20 million in cash and 25.99 million in debt, giving a net cash position of 34.22 million.
| Cash & Cash Equivalents | 60.20M |
| Total Debt | 25.99M |
| Net Cash | 34.22M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 112.58M |
| Book Value Per Share | 0.67 |
| Working Capital | 53.29M |
Cash Flow
In the last 12 months, operating cash flow was -79.63 million and capital expenditures -5,795, giving a free cash flow of -79.63 million.
| Operating Cash Flow | -79.63M |
| Capital Expenditures | -5,795 |
| Free Cash Flow | -79.63M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -32,393.53% |
| Pretax Margin | -49,003.28% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ETR:9VC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.84% |
| Shareholder Yield | -0.84% |
| Earnings Yield | -56.59% |
| FCF Yield | -31.25% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ETR:9VC has an Altman Z-Score of -4.12. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.12 |
| Piotroski F-Score | n/a |